These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17567830)

  • 41. HCV Elimination in the US Department of Veterans Affairs.
    Gonzalez R; Park A; Yakovchenko V; Rogal S; Chartier M; Morgan TR; Ross D
    Clin Liver Dis (Hoboken); 2021 Jul; 18(1):1-6. PubMed ID: 34484696
    [No Abstract]   [Full Text] [Related]  

  • 42. Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis.
    Ioannou GN; Tang W; Beste LA; Tincopa MA; Su GL; Van T; Tapper EB; Singal AG; Zhu J; Waljee AK
    JAMA Netw Open; 2020 Sep; 3(9):e2015626. PubMed ID: 32870314
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis.
    Lui FH; Moosvi Z; Patel A; Hussain S; Duong A; Duong J; Nguyen DL
    Ann Gastroenterol; 2020; 33(3):293-298. PubMed ID: 32382233
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding.
    Moon AM; Green PK; Rockey DC; Berry K; Ioannou GN
    Aliment Pharmacol Ther; 2020 Feb; 51(3):364-373. PubMed ID: 31773763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of
    Antwi SO; Van Houten HK; Sangaralingham LR; Patel T
    Cancer Prev Res (Phila); 2019 Dec; 12(12):891-902. PubMed ID: 31451519
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals.
    Ioannou GN; Green PK; Berry K; Graf SA
    Hepatol Commun; 2019 Aug; 3(8):1124-1136. PubMed ID: 31388632
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
    Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
    Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
    Ioannou GN; Green P; Kerr KF; Berry K
    J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis C.
    Hu JH; Chang ML; Huang TJ; Yeh CT; Chiu WN; Chiang MS; Chen MY
    J Interferon Cytokine Res; 2019 Apr; 39(4):205-213. PubMed ID: 30855203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New Treatments for Hepatitis C.
    Ho SB; Ma A; Smith JP
    Fed Pract; 2015 Feb; 32(Suppl 2):25S-31S. PubMed ID: 30766109
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis.
    Ioannou GN; Green P; Lowy E; Mun EJ; Berry K
    PLoS One; 2018; 13(9):e0204412. PubMed ID: 30260995
    [TBL] [Abstract][Full Text] [Related]  

  • 52. No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
    Mun EJ; Green P; Berry K; Ioannou GN
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):47-52. PubMed ID: 30142097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
    Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K
    J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.
    Benhammou JN; Dong TS; May FP; Kawamoto J; Dixit R; Jackson S; Dixit V; Bhattacharya D; Han SB; Pisegna JR
    Pharmacol Res Perspect; 2018 Apr; 6(2):e00379. PubMed ID: 29484189
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.
    Chida T; Kawata K; Ohta K; Matsunaga E; Ito J; Shimoyama S; Yamazaki S; Noritake H; Suzuki T; Suda T; Kobayashi Y
    Gut Liver; 2018 Mar; 12(2):201-207. PubMed ID: 29212314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    Ioannou GN; Green PK; Berry K
    J Hepatol; 2017 Sep; ():. PubMed ID: 28887168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies.
    Wohl DA; Allmon AG; Evon D; Hurt C; Reifeis SA; Thirumurthy H; Straub B; Edwards A; Mollan KR
    Open Forum Infect Dis; 2017; 4(2):ofx095. PubMed ID: 28695144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
    Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.
    Johnson K; Green PK; Ioannou GN
    J Viral Hepat; 2017 Nov; 24(11):966-975. PubMed ID: 28585416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review.
    Desbois AC; Cacoub P
    World J Gastroenterol; 2017 Mar; 23(9):1697-1711. PubMed ID: 28321170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.